EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Robert Haddad, Jérôme Fayette, Maria Teixeira, Kumar Prabhash, Ricard Mesia, Andrzej Kawecki, Arunee Dechaphunkul, José Dinis, Ye Guo, Muneyuki Masuda, Ching-Yun Hsieh, Maria Grazia Ghi und 12 weitere

JAMA · 13.05.2025 · 333 (18) · 1599

DOI: 10.1001/jama.2025.1483 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 13.05.2025. Verfasst von Robert Haddad und 23 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, Massachusetts. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Treating locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) involves any combination of surgery, radiation, and chemotherapy, followed by routine monitoring for local recurrence or distant metastases. Given the poor patient outcomes, a significant unmet clinical need for improved treatment options remains.

Objective

To evaluate efficacy and safety of maintenance atezolizumab in patients with LA SCCHN at high risk of disease progression after multimodal definitive treatment. Design, Setting, and Participants IMvoke010 was a phase 3, global, double-blind, randomized clinical trial. Patients were recruited at 128 sites in 23 countries between April 3, 2018, and February 14, 2020 (clinical cutoff date: September 27, 2023). Eligible patients had LA SCCHN (stage IVa/IVb involving the oral cavity, larynx, hypopharynx, or human papillomavirus–negative oropharynx, or stage III human papillomavirus–positive oropharynx [ AJCC Cancer Staging Manual, eighth edition]) without disease progression after multimodal definitive treatment.

Intervention

Patients were randomized (1:1) to receive atezolizumab 1200 mg or placebo every 3 weeks for 1 year or until disease recurrence, disease progression, unacceptable toxicity, or consent withdrawal. Main Outcomes and Measures The primary end point was investigator-assessed event-free survival. Other end points included overall survival and safety.

Results

Overall, 406 patients were randomized to receive atezolizumab (n = 203) or placebo (n = 203); baseline demographics were balanced between both treatment groups (<65 years, 142 [70.0%] vs 155 [76.4%]; male, 168 [82.8%] vs 174 [85.7%]; Asian, 68 [35.6%] vs 61 [31.0%]; Black, 1 [0.5%] vs 1 [0.5%]; and White, 121 [63.4%] vs 135 [68.5%], respectively). At clinical cutoff (median follow-up, 46.5 months), median investigator-assessed event-free survival was 59.5 months (95% CI, 46.8 to not estimable) with atezolizumab vs 52.7 months (95% CI, 41.4 to not estimable) with placebo (hazard ratio, 0.94; 95% CI, 0.70-1.26; P = .68). There was no difference in overall survival between atezolizumab and placebo (24-month overall survival, 82.0% vs 79.2%, respectively). No new or unexpected safety signals were identified. Conclusions and Relevance In this study, atezolizumab did not improve clinical outcomes in patients with LA SCCHN at high risk of disease progression after multimodal definitive treatment. These data contribute to evidence on the limited activity of checkpoint inhibitors in the global population of this disease setting. Overall, the role of immunotherapy for patients with LA SCCHN remains to be determined. Trial Registration ClinicalTrials.gov Identifier: NCT03452137

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckImmune Checkpoint InhibitorsAdultAgedFemaleHumansMaleMiddle AgedDisease ProgressionDouble-Blind MethodNeoplasm StagingDisease-Free SurvivalTreatment OutcomeNeoplasm Recurrence, Local

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Centre Leon Berard, Département d'Hématologie et d'Oncologie, Lyon, France.
  • IPO de Coimbra, Servico de Oncologia Medica, Coimbra, Portugal.
  • Tata Memorial Hospital, Department of Medical Oncology, Mumbai, India.
  • Catalan Institute of Oncology, B-ARGO Group, IGTP, Badalona, Catalonia, Spain.
  • National Research Institute of Oncology, Warsaw, Poland.

Zitieren

APA

Haddad, R., Fayette, J., Teixeira, M., Prabhash, K., Mesia, R., Kawecki, A., Dechaphunkul, A., Dinis, J., Guo, Y., Masuda, M., Hsieh, C. Y., Ghi, M. G., Vaz de Melo Sette, C., Harrington, K., Tahara, M., Saba, N. F., Lau, A., Jiang, T., Yan, Y., …, & Wong, D. J. (2025). Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck. JAMA, 333(18), 1599. https://doi.org/10.1001/jama.2025.1483

Vancouver

Haddad R, Fayette J, Teixeira M, Prabhash K, Mesia R, Kawecki A, et al. Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck. JAMA. 2025;333(18):1599. doi:10.1001/jama.2025.1483

BibTeX
@article{Haddad2025,
  author = {Haddad, Robert and Fayette, Jérôme and Teixeira, Maria and Prabhash, Kumar and Mesia, Ricard and Kawecki, Andrzej and Dechaphunkul, Arunee and Dinis, José and Guo, Ye and Masuda, Muneyuki and Hsieh, Ching-Yun and Ghi, Maria Grazia and Vaz de Melo Sette, Claudia and Harrington, Kevin and Tahara, Makoto and Saba, Nabil F and Lau, Agnes and Jiang, Tao and Yan, Yibing and Ballinger, Marcus and Kaul, Monika and Matheny, Christina and Cuchelkar, Vaikunth and Wong, Deborah J},
  title = {Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck},
  journal = {JAMA},
  year = {2025},
  volume = {333},
  number = {18},
  pages = {1599},
  doi = {10.1001/jama.2025.1483}
}
Kostenlos starten →